Further investigations on PCa tissues or liquid biopsies from CRPC patients are needed to validate the clinical usefulness of the hnRNP K–AR-related signature and to evaluate whether some of the proteins included in our signature might become potential targets for new drugs development. This evidence concerns the gene HNRNPK and posterior cortical atrophy.